OTCBB:LKYSF
Delisted

Numinus Wellness Stock News

etoro logo Buy LKYSF
*Your capital is at risk
$0.390
+0 (+0%)
At Close: Aug 17, 2022
Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.
Trifecta of psychedelics healing and wellness solutions Numinus Bioscience is a Health Canada-licensed lab Numinus R&D is developing psychedelic-assisted therapeutic protocols Numinus Health supports
Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV:NUMI) (OTCQX:NUMIF) announced its fiscal fourth quarter and full-year results Thursday for the periods ended August 31,
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) closed out its fiscal fourth quarter with a strong $59.2 million cash balance and improved revenue following its acquisition of Canadian healthcare start-
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) has announced novel, proprietary methods - developed and validated in-house - for screening psychedelic mushroom compounds.   The testing will be avail
Numinus Wellness Inc said it has received conditional approval for listing on the Toronto Stock Exchange (TSX), moving up from its listing on the TSX Venture Exchange. "This is an important milesto
Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) said it has secured two new psychedelic clinics in Canada to host a key study into MDMA-assisted psychotherapy for PTSD (Post-Traumatic Stress Disorder)
Numinus Wellness Inc said it has secured two new psychedelic clinics to host the Canadian sites of a key study into MDMA-assisted psychotherapy for PTSD. The MAPS Public Benefit Corporation (MAPS PBC)
Numinus Wellness Inc. revealed that it has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived psilocybin extract.
Numinus Wellness Inc closed out its fiscal third quarter with a strong $63.2 million cash position, surging revenue from its clinic operation, trial advances and by making a strategic push into psyche
Numinus Wellness Inc closed out its fiscal third quarter with a strong $63.2 million cash position, surging revenue from its clinic operation, trial advances and by making a strategic push into psyche
Numinus Wellness Inc (CVE:NUMI) (OTCMKTS:LKYSF) (FRA:LR23) announced it had received Health Canada approval for the MAPS-sponsored open label study of MDMA-assisted therapy for post-traumatic stress d
Numinus Wellness Inc (CVE:NUMI) announced it had struck an agreement to acquire the Neurology Centre of Toronto (NCT) in a deal worth up to $1 million. The Neurology Centre is a fully operational clin
Numinus Wellness Inc (CVE:NUMI) has announced that its subsidiary Numinus Bioscience Inc has filed a provisional patent application in the US for the rapid production process that generates therapeut
These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF. The post 3 Psychedelics Stocks Getting High Thanks to the Ne
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE